Holen Sie sich die Stockscreener-App
21.96
0.97%
0.21
Handel nachbörslich:
21.96
Schlusskurs vom Vortag:
$21.75
Offen:
$21.57
24-Stunden-Volumen:
849.24K
Relative Volume:
0.90
Marktkapitalisierung:
$2.61B
Einnahmen:
$434.48M
Nettoeinkommen (Verlust:
$68.15M
KGV:
21.74
EPS:
1.01
Netto-Cashflow:
$114.96M
1W Leistung:
+0.87%
1M Leistung:
+9.80%
6M Leistung:
+49.18%
1J Leistung:
+66.87%
1-Tages-Spanne:
$21.41
$22.05
1-Wochen-Bereich:
$21.20
$22.27
52-Wochen-Spanne:
$12.27
$22.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Q3 2024 Earnings Preview - MSN
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
DekaBank Deutsche Girozentrale Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Zacks.com featured highlights include Vertiv, Limbach, Atour Lifestyle and Catalyst Pharmaceuticals - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Boosted by Allspring Global Investments Holdings LLC - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month HighHere's Why - MarketBeat
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago - MSN
Catalyst Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024 - The Manila Times
50,500 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Purchased by Toth Financial Advisory Corp - MarketBeat
Friedenthal Financial Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Catalyst Pharmaceuticals stock hits 52-week high of $21.67 By Investing.com - Investing.com Australia
STATE STREET CORP's Strategic Reduction in Catalyst Pharmaceuticals Holdings - GuruFocus.com
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Bfsg LLC Invests $3 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Catalyst Pharmaceuticals stock hits 52-week high of $21.67 - Investing.com
Tourette Syndrome Drug Market 2024-2034- Abide Therapeutics Inc, Catalyst Pharmaceuticals Inc, Neurocrine Biosciences In – IndiaPolitics.com - IndiaPolitics.com
Cubist Systematic Strategies LLC Sells 233,967 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Zacks.com featured highlights include Barrick Gold, Catalyst Pharmaceuticals, Allegiant Travel and America Movil - Yahoo Finance
Oliver Luxxe Assets LLC Takes $676,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Squarepoint Ops LLC Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Zacks Research Weighs in on Catalyst Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:CPRX) - MarketBeat
With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners - Yahoo Finance
Catalyst Pharmaceuticals Inc (CPRX) Q2 2024 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Catalyst Pharmaceuticals Inc (CPRX) Q2 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts - The Manila Times
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Q3 2025 EPS Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Boosted by Zacks Research - MarketBeat
Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Latest Stock Performance A Reflection Of Its Financial Health? - Simply Wall St
AQR Capital Management LLC Acquires 227,321 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):